-/3- 0,5 JC04 Rec'd PCT/PTO 11 JUL 2005

Express Mail Label No. Dated:

Docket No.: 20489/0202976-US0

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:

Chang S. Park et al.

Application No.: 10/537,319 €

Filed: June 1, 2005

For:

INHIBITOR OF ANGIOGENESIS AND KIT

FOR TREATING CANCER COMPRISING

THE INHIBITOR

Confirmation No.: N/A

Art Unit: N/A

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37, CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR) 1.97(b)(2)).

Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), a copy of the United States Patent on PTO/SB/08a is not submitted.

Application No.: 10/537;319 2 Docket No.: 20489/0202976-US0

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: July 11, 2005

Respectfully submitted,

Paul Fields

Registration No.: 20,298 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requir

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

ired to respond to a collection of information unless it contains a valid OMB control number.				
Complete if Known				
Application Number	10/537,319			
Filing Date	June 1, 2005			
First Named Inventor	Chang S. Park			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	20489/0202976-US0			

U.S. PATENT DOCUMENTS					
Examiner Cite Initials* No.	C14.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where
		Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear
	AA	US-6,610,534-B2	08-26-2003	Liau et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	۳°	
	BA	WO-03/092667-A1	11-13-2003	Choi, Jin-Hee et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	XIAODONG SHU, et al.; "Sphingosine kinase mediates Vascular Endothelial Growth Factor- Induced Activation of Ras and Mitogen-Activated Protein Kinases"; Molecular and Cellular Biology, November 2002, Vol. 22, No. 22, pages 7758-7768.			
	СВ	CHAN WOO KIM, et al.; "Extracellular Membrane Vesicles from Tumor Cells Promote Angiogenesis via Sphingomyelin"; Cancer Research, November 1, 2002, 62(61), pages 6312-6317.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.